# JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

> **NCT04208464** · PHASE2 · COMPLETED · sponsor: **University of Manchester** · enrollment: 15 (actual)

## Conditions studied

- Idiopathic Inflammatory Myopathies

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT04208464
- **Lead sponsor:** University of Manchester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-07
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-09-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04208464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04208464, "JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04208464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*